NEC Laboratories Europe and Data-Driven.AI are collaborating to advance medical diagnoses with the use of AI and machine learning (ML).
The companies said that when detected early, many diseases can be managed or resolved without serious complications. However, conditions may already be advanced by the time recognisable symptoms are presented. In addition, doctors may miss symptoms that call for a specific range of tests to confirm a diagnosis.
Go deeper with GlobalData
To address these challenges, Germany-based NEC and Italy-based Data-Drive.AI plan to use ML to identify unique patterns in blood results that may call for further investigation.
NEC said this would be achieved by applying ML to its data repository that combines blood analysis and other patient information to build condensed representations of a patient’s health – a provision used to help predict future patient conditions through additional recommended testing.
Giampaolo Pileggi, project manager in Biomedical AI at NEC Laboratories Europe, commented: “The human body is incredibly complex, its organ systems working in harmony to keep us healthy.
“Over time, a minor issue with one system can quickly become serious and affect others. Doctors can greatly benefit from AI systems that can uncover hidden correlations in medical data, detecting even the slightest anomalies that may indicate an imbalance in the body.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to Data-Driven.AI founder and CEO Diego Facchini, the continuous training and refinement of AI models holds the potential to “revolutionise” early disease detection by identifying subtle deviations in a person’s health that could be overlooked by traditional methods.
“By leveraging ML algorithms and vast datasets, AI can enhance diagnostic accuracy and improve predictive capabilities, which represent a significant breakthrough in the field of disease detection and prevention.”
GlobalData’s recent ‘The Future of Work in Healthcare‘ report outlined how AI can be used to help improve both disease diagnosis and treatment plans, leading to better patient outcomes. In particular, it highlights how AI can be used to help to interpret visual data such as scans and to determine therapy approaches, along with its potential to identify patterns as NEC and Data-Driven.AI are collaborating to advance.
AI continues to have an appreciable influence in the pathology field. Proscia, the developer of Concentriq, a digital pathology platform in use by 16 of the top 20 pharmaceutical companies, recently secured $50m towards the further development of its AI-driven digital pathology platform.
